Citations

Clear

80 citation(s) found for "Pignolo, RJ".

Longitudinal and Flare-Up-Specific Biomarkers in Fibrodysplasia Ossificans Progressiva (FOP): Data from a Global Natural History Study
Pignolo, RJ, Semler, JO, Mukaddam, Mona Al , Cunto, Carmen De , Hsiao, EC, Harnett, Kathleen, Marino, Rose , Kaplan, Frederick S. , Kaplan, Frederick S , Baujat, Geneviève , Keen, Richard

Mayo Clinic

Osteologie | April 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1722146 Get It

Use of Assistive Devices and Adaptations by Individuals with Fibrodysplasia Ossificans Progressiva (FOP): Data from a Global Natural History Study
Hsiao, EC, Semler, JO, Mukaddam, Mona Al , Cunto, Carmen De , Pignolo, RJ, Harnett, Kathleen, Marino, Rose , Baujat, Geneviève , Keen, Richard , Kaplan, Frederick S.

Mayo Clinic

Osteologie | April 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1722145 Get It

Medications Used by Individuals with Fibrodysplasia Ossificans Progressiva (FOP): Data from a Global Natural History Study
Stockklausner, Clemens , Mukaddam, Mona Al , Cunto, Carmen De , Hsiao, EC, Pignolo, RJ, Harnett, Kathleen, Marino, Rose , Kaplan, Frederick S. , Kaplan, Frederick S , Keen, Richard , Baujat, Geneviève

Mayo Clinic

Osteologie | April 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1722142 Get It

A Global Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes
Mukaddam, Mona Al , Stockklausner, Clemens , Pignolo, RJ, Brown, MA, Cunto, Carmen De , Rocco, M Di, Hsiao, EC, Sang, K-H Le Quan, Strahs, Andrew , Marino, Rose , Kaplan, Frederick S. , Kaplan, Frederick S , Baujat, Geneviève , Rocco, M Di, Keen, Richard

Mayo Clinic

Osteologie | April 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1722141 Get It

Bone Aging, Cellular Senescence, and Osteoporosis
Pignolo, Robert J. , Law, Susan F., Chandra, Abhishek , Chandra, Abhishek

Mayo Clinic

JBMR Plus | March 15, 2021 | Volume: 5 | Issue: 4 | Pages: No page available

10.1002/jbm4.10488 | PMID 33869998 Get It

ABSTRACT Changes in aging bone that lead to osteoporosis are mediated at multiple levels, including hormonal alterations, skeletal unloading, and accumulation of senescent cells. This pathological interplay is superimposed upon medical conditions, potentially bone‐wasting medications, modifiable and unmodifiable personal risk factors, and genetic predisposition that accelerate bone loss with aging. In this study, the focus is on bone hemostasis and its dysregulation with aging. The major physiological changes with aging in bone and the role of cellular senescence in contributing to age‐related osteoporosis are summarized. The aspects of bone aging are reviewed including remodeling deficits, uncoupling phenomena, inducers of cellular senescence related to bone aging, roles of the senescence‐associated secretory phenotype, radiation‐induced bone loss as a model for bone aging, and the accumulation of senescent cells in the bone microenvironment as a predominant mechanism for age‐related osteoporosis. The study also addresses the rationale and potential for therapeutic interventions based on the clearance of senescent cells or suppression of the senescence‐associated secretory phenotype. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
Bone From Blood: Characteristics and Clinical Implications of Circulating Osteogenic Progenitor (COP) Cells
Feehan, Jack , Kassem, Moustapha , Pignolo, Robert J. , Duque, Gustavo , Kassem, Moustapha , Duque, Gustavo

Mayo Clinic

Journal of Bone and Mineral Research | October 29, 2020 | Volume: 36 | Issue: 1 | Pages: 12-23

10.1002/jbmr.4204 | PMID 33118647 Get It

ABSTRACT Circulating osteogenic progenitor (COP) cells are a population of cells in the peripheral blood with the capacity for bone formation, as well as broader differentiation into mesoderm-like cells in vitro. Although some of their biological characteristics are documented in vitro, their role in diseases of the musculoskeletal system remains yet to be fully evaluated. In this review, we provide an overview of the role of COP cells in a number of physiological and pathological conditions, as well as identify areas for future research. In addition, we suggest possible areas for clinical utilization in the management of musculoskeletal diseases. © 2020 American Society for Bone and Mineral Research (ASBMR).
Bridging the geroscience chasm between bench and bedside
Tung, Ericka E. , Weavers, Karen M. , Kirkland, James L. , Pignolo, Robert J.

Mayo Clinic

Gerontology & Geriatrics Education | October 9, 2020 | Volume: 43 | Issue: 2 | Pages: 250-256

10.1080/02701960.2020.1832999 | PMID 33032498 Get It

Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span
Jurk, Diana , Kirkland, James L. , Passos, João F. , Pignolo, Robert J. , Niedernhofer, Laura J. , Zhang, Lei , Miller, Jordan D. , Jurk, Diana , Passos, João F , Niedernhofer, Laura J , Zhang, Lei , Robbins, Paul D. , Khosla, Sundeep , LeBrasseur, Nathan K. , Tchkonia, Tamar

Mayo Clinic

Annual Review of Pharmacology and Toxicology | September 30, 2020 | Volume: 61 | Issue: 1 | Pages: 779-803

10.1146/annurev-pharmtox-050120-105018 | PMID 32997601 Get It

Senescence is the consequence of a signaling mechanism activated in stressed cells to prevent proliferation of cells with damage. Senescent cells (Sncs) often develop a senescence-associated secretory phenotype to prompt immune clearance, which drives chronic sterile inflammation and plays a causal role in aging and age-related diseases. Sncs accumulate with age and at anatomical sites of disease. Thus, they are regarded as a logical therapeutic target. Senotherapeutics are a new class of drugs that selectively kill Sncs (senolytics) or suppress their disease-causing phenotypes (senomorphics/senostatics). Since 2015, several senolytics went from identification to clinical trial. Preclinical data indicate that senolytics alleviate disease in numerous organs, improve physical function and resilience, and suppress all causes of mortality, even if administered to the aged. Here, we review the evidence that Sncs drive aging and disease, the approaches to identify and optimize senotherapeutics, and the current status of preclinical and clinical testing of senolytics.
SUN-344 Patients with Fibrodysplasia Ossificans Progressiva Have an Increased Prevalence of Cardiac Conduction Abnormalities
Kou, Samuel , DeCunto, Carmen, Wentworth, Kelly L. , Grogan, Donna R., Rocco, Maja Di , Mukaddam, Mona Al , Kaplan, Frederick S. , Pignolo, Robert J. , Kaplan, Frederick S , Baujat, Geneviève , Brown, Matthew A. , Keen, Richard , Hsiao, Edward C.

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.238 Get It

Abstract Background Genetic contributors to cardiac arrhythmias often found in cardiovascular conduction pathway and channel proteins. However, genes outside of these categories can contribute to cardiovascular conduction abnormalities. Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized by large volumes heterotopic ossification caused by a highly recurrent R206H mutation in the ACVR1/Alk2 gene. This mutation produces an abnormal activation of the bone morphogenetic pathway (BMP) pathway in response to Activin A. Prior studies suggested an increased risk of cardiopulmonary complications in FOP1. We examined patients in a Natural History Study (NHS) of FOP (NCT02322255) to better understand their cardiovascular risk. Methods The NHS is an ongoing 3 year international multi-center cross-sectional study of 114 patients with FOP (ages 4–56 years) genetically verified to have the AVCR1 R206H mutation. Patients at baseline and 12 months were assessed by electrocardiogram (ECG). Abnormal lead placements were excluded. ECG readings were assessed in a central ECG laboratory. Results At baseline, 45.3% (48/106) of ECGs showed conduction abnormalities. The majority of these abnormalities were classified as nonspecific intraventricular conduction delay (37.7% of all ECGs). For patients > 18 years old, 22.7% (10/44) had conduction abnormalities, which was significantly higher than previously reported in the healthy population (5.9%; n=3978)2 (proportional t-test; p<0.00001). FOP patients < 18 years of age also had an extremely high prevalence of conduction abnormalities (60.3%, 38/61). The NHS 12-month follow up data showed similar prevalence. The high frequency of conduction abnormalities did not correlate with the presence of chest wall deformities or scoliosis, abnormal pulmonary function test results, increased cumulative analog joint involvement scale (CAJIS) scores, or abnormal echocardiograms. Conclusions Our results show that some patients with FOP may have subclinical conduction abnormalities. These ECG changes appear to be independent of chest wall deformities or scoliosis, although ectopic bone may make ECG measurement in FOP patients challenging. Though there is no reported association of FOP with clinically significant heart block to date and clinical implications for cardiovascular risk remain unclear, knowledge about these ECG changes may be important for planning clinical care and clinical trials of investigational agents in patients with FOP. Further studies of how the AVCR1 R206H activating mutation and BMP signaling changes cardiac conduction are needed to better understand the mechanistic link. References (1)Hingorani et al. Indian J Med Res. 2012; 135:322–330 (2)Kussmaul et al. Clinical Orthopaedic Related Research. 1998; 346:104–109
OR29-05 A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes
Mukaddam, Mona Al , Pignolo, Robert J. , Cunto, Carmen De , Rocco, Maja Di , Strahs, Andrew , Marino, Rose , Kaplan, Frederick S. , Kaplan, Frederick S , Baujat, Geneviève , Brown, Matthew , Hsiao, Edward C. , Keen, Richard , Sang, Kim‐Hanh Le Quan

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.254 Get It

Abstract Background: FOP is an ultra-rare, severely disabling genetic disorder characterized by episodic flare-ups and heterotopic ossification (HO) leading to restricted movement, physical disability, and early death. FOP may initially be misdiagnosed in ~90% of individuals leading to unnecessary and often harmful interventions. Patients with FOP are diagnosed and managed by multiple specialties, including endocrinologists. Data from an ongoing, prospective, longitudinal, global, natural history study (NCT02322255) were used to investigate the progression of FOP, HO formation, and impact on physical functioning over time. We present results from the first 12 months of the 3-year study. Methods: Males and females with FOP and a documented ACVR1 R206H mutation participated. HO volume was assessed by low-dose whole body computed tomography (WBCT) scan, excluding the head. All imaging was interpreted at a blinded, central laboratory using pre-specified procedures. Functional outcomes were evaluated using the Cumulative Analogue Joint Involvement Scale (CAJIS; for each joint: score=0 represents <10% involvement, score=1 represents 10–90% involvement, and score=2 represents >90% ankylosed across 15 major joints; total score range 0 to 30 [higher scores indicate more severe mobility limitations]) and the FOP Physical Function Questionnaire (FOP-PFQ; percent total score). Changes from Baseline at Month 12 were evaluated for new HO volume, CAJIS, and FOP-PFQ. Results: Of 114 participants (pts) with Baseline data, 99 (4 to 56 years at enrollment; mean 17 years of age; 56% male) also had a Month 12 assessment. A total of 93 pts had evaluable WBCT scans at Baseline and Month 12 and were included in the HO analysis. In total, 40% (37/93) of pts had new HO over 12 months; the mean volume of new HO in these pts was 57,706 mm3 (SD=100,079 mm3; median=20,753 mm3; range: 522 to 438,826 mm3). Of the pts with new HO, 65% (24/37) reported at least one flare-up (mean rate of 2.3 flare-ups/year). Over 12 months, 60% (56/93) of pts did not have new HO; 43% (24/56) of them reported at least one flare-up (mean rate of 1.8 flare-ups/year). Mean changes from Baseline in CAJIS and FOP-PFQ were minimal: CAJIS: 0.6 (SD=2.4; median=1.0; n=99) and FOP-PFQ: 4.4% (SD=11.2; median=3.7%; n=90); and were similar across pts with or without new HO. Conclusions: In participants with FOP, although deterioration of physical function is expected over a patient’s lifetime, CAJIS and FOP-PFQ scores did not worsen significantly in the relative short-term of this study. However, HO volume, quantified by WBCT, increased over the course of 12 months. These results show that measuring HO may be a viable way to monitor changes in FOP over short periods of time.